In a recent key advance, evinacumab, a monoclonal antibody targeting ANGPTL3, was approved for use in homozygous familial hypercholesterolemia, based on reduction in LDL-C by 47% via non-LDLR dependent pathways18. The gene discussed is LDLR; the disease is familial hypercholesterolemia.